Abstract
Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Current Drug Targets
Title:Matrix Metalloproteinases as Drug Targets in Preeclampsia
Volume: 14 Issue: 3
Author(s): Ana C.T. Palei, Joey P. Granger and Jose E. Tanus-Santos
Affiliation:
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Abstract: Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Export Options
About this article
Cite this article as:
C.T. Palei Ana, P. Granger Joey and E. Tanus-Santos Jose, Matrix Metalloproteinases as Drug Targets in Preeclampsia, Current Drug Targets 2013; 14 (3) . https://dx.doi.org/10.2174/1389450111314030004
DOI https://dx.doi.org/10.2174/1389450111314030004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions
Current Clinical Pharmacology Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
Current Cancer Drug Targets Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
Current Vascular Pharmacology Enzymes Inhibition and Antidiabetic Effect of Isolated Constituents from Callistemon lanceoalatus
The Natural Products Journal Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry New Drugs for Epidural Analgesia
Current Drug Targets Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology Various Presentations of Preeclampsia at Tertiary Care Hospital of Sindh: A Cross-Sectional Study
Current Hypertension Reviews Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Matrix Metalloproteinases in Lung Diseases
Current Protein & Peptide Science New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients
Current Vascular Pharmacology Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology